• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by NewAmsterdam Pharma Company N.V.

    6/5/26 4:41:20 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NAMS alert in real time by email
    S-8 1 nams-20260605.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on June 5, 2026

     

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    NewAmsterdam Pharma Company N.V.

    (Exact name of registrant as specified in its charter)

     

     

     

    The Netherlands

    Not applicable

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    Gooimeer 2-35

    1411 DC Naarden

    The Netherlands

    (Address of Principal Executive Offices)

     

     

     

    Not applicable

    (Zip Code)

    NewAmsterdam Pharma Company N.V. 2026 Employee Stock Purchase Plan

    (Full title of the plan)

    NewAmsterdam Pharma Corporation

    1730 Main Street, Suite #226

    Weston, FL 33326

    (Name and address of agent for service)

     

    Tel: (305) 627-3081

    (Telephone number, including area code, of agent for service)

    Copies to:

    Michael F. Marino

    NewAmsterdam Pharma Corporation

    1730 Main Street, Suite #226

    Weston, FL 33326

    Tel: (305) 627-3081

     

    Brian K. Rosenzweig

    Kerry S. Burke

    Covington & Burling LLP

    30 Hudson Yards

    New York, NY 10001

    Tel: (212) 841-1000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     


     

    Large accelerated filer x

    Accelerated filer o

    Non-accelerated filer o

    Smaller reporting company o

    Emerging growth company o

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

     


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information

     

    The documents containing the information specified in Part I will be delivered in accordance with Rule 428(b) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not required to be, and are not, filed with the U.S. Securities and Exchange Commission (the “Commission”), either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents, and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of the Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    Item 2. Registrant Information and Employee Plan Annual Information

     

    The written statement required by Item 2 of Part I is included in documents that will be delivered to participants in the plan covered by this Registration Statement pursuant to Rule 428(b) of the Securities Act. Such documents are not being filed with the Commission as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

     


     

    PART II
    INFORMATION REQUIRED IN REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The documents listed below have been filed with the Commission by the Registrant and are incorporated herein by reference to the extent not superseded by documents subsequently filed:

    1)
    the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on February 18, 2026;
    2)
    the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the Commission on May 7, 2026;
    3)
    the Company’s Current Reports on Form 8-K filed with the Commission on April 24, 2026 and June 3, 2026; and
    4)
    the description of the Ordinary Shares contained in the registration statement on Form 8-A, filed with the Commission on November 22, 2022, as the description therein has been updated and superseded by the description of the Ordinary Shares contained in Exhibit 4.4 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 26, 2025, and including any amendments or reports filed for the purpose of updating such description.

    All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in the Registration Statement and to be a part hereof from the date of the filing of such documents. The Company is not incorporating by reference any document or portion thereof, whether specifically listed above or to be filed in the future, that is not deemed “filed” with the Commission.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein) modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    None.

    Item 6. Indemnification of Directors and Officers.

    The Registrant is a public limited liability company (naamloze vennootschap).

    Under Dutch law, the Registrant’s directors may be held liable for damages in the event of improper or negligent performance of their duties. They may be held liable for damages to the Registrant and to third parties for infringement of the Registrant’s articles of association (the “Articles of Association”) or of certain provisions of Dutch law. In certain circumstances, they may also incur other specific civil, administrative and criminal liabilities. Subject to certain exceptions, the Articles of Association provide for indemnification of the Registrant’s current and former directors and other current and former officers and employees as designated by the Registrant’s board of directors. No indemnification under the Articles of Association will be given to an indemnified person:

     


     

    •
    if a competent court or arbitral tribunal has established, without having (or no longer having) the possibility for appeal, that the acts or omissions of such indemnified person that led to the financial losses, damages, expenses, suit, claim, action or legal proceedings as described above are of an unlawful nature (including acts or omissions which are considered to constitute malice, gross negligence, intentional recklessness and/or serious culpability attributable to such indemnified person);
    •
    to the extent that his or her financial losses, damages and expenses are covered under insurance and the relevant insurer has settled, or has provided reimbursement for, these financial losses, damages and expenses (or has irrevocably undertaken to do so);
    •
    in relation to proceedings brought by such indemnified person against the Registrant, except for proceedings brought to enforce indemnification to which he or she is entitled pursuant to the Articles of Association, pursuant to an agreement between such indemnified person and the Registrant, which has been approved by the Registrant or pursuant to insurance taken out by us for the benefit of such indemnified person; and
    •
    for any financial losses, damages or expenses incurred in connection with a settlement of any proceedings effected without the Registrant’s prior consent.

    Under the Articles of Association, the Registrant’s board of directors may stipulate additional terms, conditions and restrictions in relation to the indemnification described above.

    The Registrant has also entered into indemnification agreements with each of our directors and executive officers providing for procedures for indemnification and advancements by the Registrant of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to the Registrant or, at the Registrant’s request, service to other entities, as officers or directors to the maximum extent permitted by Dutch law and subject to the exceptions provided in such agreements.

    Item 7. Exemption From Registration Claimed.

    Not applicable.

    Item 8.

    Exhibits.

     

     

     

     

    Exhibit
    Number

    Description

     

     

    4.1

    English translation of Articles of Association of NewAmsterdam Pharma Company N.V. (incorporated by reference to Exhibit 1.1 to the Shell Company Report on Form 20-F (Reg. No. 001-41562) filed with the Commission on November 28, 2022).

     

     

    5.1*

    Opinion of NautaDutilh N.V., regarding validity of the Ordinary Shares.

     

     

    23.1*

    Consent of NautaDutilh N.V. (included in Exhibit 5.1).

     

     

    23.2*

    Consent of Deloitte Accountants B.V., independent registered public accounting firm of NewAmsterdam Pharma Company N.V.

     

     

    24.1*

    Power of Attorney (included on the signature page to this Registration Statement).

     

     

    99.1

    NewAmsterdam Pharma Company N.V. 2026 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on June 3, 2026).

     

     

     

    107*

    Filing Fee Table.

    * Filed herewith.

     

     


     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Weston, Florida, on June 5, 2026.

     

     

     

    NewAmsterdam Pharma Company N.V.

     

     

    By:

    /s/ Michael Davidson

    Name:

     

    Michael Davidson, M.D.

    Title:

     

    Chief Executive Officer

    SIGNATURES AND POWERS OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Michael Davidson, Ian Somaiya and Michael F. Marino, each acting alone, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead in any and all capacities, in connection with this Registration Statement, including to sign in the name and on behalf of the undersigned, this registration statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the Securities Act and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto such attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or her substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

    Name

    Title

    Date

    /s/ Michael Davidson

    Chief Executive Officer and Director

    June 5, 2026

    Michael Davidson, M.D.

    (Principal Executive Officer)

    /s/ Ian Somaiya

    Chief Financial Officer

    June 5, 2026

    Ian Somaiya

    (Principal Financial Officer)

    /s/ Louise Kooij

    Chief Accounting Officer

    June 5, 2026

    Louise Kooij

    (Principal Accounting Officer)

    /s/ William H. Lewis

    Chairman of the Board of Directors

    June 5, 2026

    William H. Lewis, J.D., M.B.A.

    /s/ Adele Gulfo

    Director

    June 5, 2026

    Adele Gulfo

    /s/ Wouter Joustra

    Director

    June 5, 2026

    Wouter Joustra

     


     

    Name

    Title

    Date

     

    /s/ John Kastelein

    Director

    June 5, 2026

    John Kastelein, M.D., Ph.D., FESC

    /s/ Louis Lange

    Director

    June 5, 2026

    Louis Lange, M.D., Ph.D.

    /s/ Mark C. McKenna

    Director

    June 5, 2026

    Mark C. McKenna

     

     

     

    /s/ John W. Smither

    Director

    June 5, 2026

    John W. Smither

    /s/ James N. Topper

    Director

    June 5, 2026

    James N. Topper, M.D., Ph.D.

     

     

     

     

    /s/ Janneke van der Kamp

    Director

    June 5, 2026

    Janneke van der Kamp

     

     

     


     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE COMPANY

    Pursuant to the requirement of the Securities Act, the undersigned, the duly authorized representative in the United States of NewAmsterdam Pharma Company N.V., has signed this registration statement in the United States, on the 5th day of June, 2026.

     

     

     

    NewAmsterdam Pharma Corporation

     

     

    By:

    /s/ Michael Davidson

    Name:

    Michael Davidson, M.D.

    Title:

    President

     

     

     


    Get the next $NAMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAMS

    DatePrice TargetRatingAnalyst
    3/18/2026$57.00Buy
    Truist
    10/20/2025$52.00Buy
    H.C. Wainwright
    8/25/2025$45.00Overweight
    Wells Fargo
    7/17/2025$27.00Neutral
    Goldman
    6/17/2025$42.00Buy
    Citigroup
    6/10/2025$44.00Buy
    Stifel
    6/4/2025$42.00Overweight
    Cantor Fitzgerald
    12/30/2024$48.00Buy
    H.C. Wainwright
    More analyst ratings

    $NAMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on NewAmsterdam Pharma with a new price target

    Truist initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $57.00

    3/18/26 3:54:27 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on NewAmsterdam Pharma with a new price target

    H.C. Wainwright resumed coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $52.00

    10/20/25 8:45:44 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on NewAmsterdam Pharma with a new price target

    Wells Fargo initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $45.00

    8/25/25 8:22:07 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    SEC Filings

    View All

    SEC Form S-8 filed by NewAmsterdam Pharma Company N.V.

    S-8 - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)

    6/5/26 4:41:20 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.

    SCHEDULE 13G/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    6/4/26 6:32:08 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)

    6/3/26 7:58:30 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Topper James N bought $15,639 worth of Ordinary Shares (660 units at $23.70) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/17/25 5:22:34 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $31,487 worth of Ordinary Shares (1,260 units at $24.99) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/10/25 5:19:10 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $11,294 worth of Ordinary Shares (471 units at $23.98) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    8/13/25 4:49:54 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation

    NewAmsterdam REMBRANDT clinical trial to leverage Caristo CaRi-Heart® and CaRi-PlaqueTM technologies for coronary inflammation and plaque measurements and monitoring STAMFORD, Conn. and OXFORD, England, Oct. 14, 2025 /PRNewswire/ -- Caristo Diagnostics, on a mission to transform the diagnosis and treatment of cardiovascular disease, announced its role as the worldwide imaging core lab for NewAmsterdam Pharma's REMBRANDT Cardiovascular Imaging Trial – overseeing all coronary plaque and inflammation measurements and monitoring. The REMBRANDT trial, sponsored by NewAmsterdam Phar

    10/14/25 7:00:00 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

    Frazier Life Sciences XII, L.P. will focus on creating and investing in pioneering companies developing novel therapeutics Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies. "We appreciate the continued support of our limited partners, many of whom have been with us since the launch of o

    7/31/25 7:00:00 AM ET
    $ARQT
    $MIRM
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

    NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

    4/17/25 4:01:00 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Kooij Louise Frederika exercised 65,000 units of Ordinary Shares at a strike of $10.07 and sold $2,319,850 worth of Ordinary Shares (65,000 units at $35.69) as part of a pre-agreed trading plan (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    5/27/26 4:30:12 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lange Louis G sold $1,357,230 worth of Ordinary Shares (44,619 units at $30.42), decreasing direct ownership by 81% to 10,360 units (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    3/12/26 4:25:23 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lange Louis G sold $828,950 worth of Ordinary Shares (28,186 units at $29.41) and exercised 44,619 in-the-money units of Ordinary Shares at a strike of $11.50, increasing direct ownership by 431% to 54,979 units (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    3/10/26 8:58:01 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Leadership Updates

    Live Leadership Updates

    View All

    NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

    NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the

    4/17/25 4:01:00 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

    enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

    5/15/24 4:05:00 PM ET
    $ENGN
    $NAMS
    $NKTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

    New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors. "We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs. "His expertise as a physician and researcher in the field of cardiometabolism, deep experience in clinical development, and track record leading multiple successful compa

    4/9/24 8:00:00 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NAMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care